CTOs on the Move

LumiThera

www.lumithera.com

 
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.lumithera.com
  • 19578 10th Avenue NorthEast Suite 200
    Poulsbo, WA USA 98370
  • Phone: 844.342.3333

Executives

Name Title Contact Details

Funding

LumiThera raised $10M on 01/13/2020
LumiThera raised $14M on 07/08/2020

Similar Companies

Optimetrics Inc

Optimetrics Inc is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hospitality Dental Group

Hospitality Dental Group is a Palm Desert, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forrester

Forrester is a Long Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Great Plains Regional Medical Center

Great Plains Regional Medical Center is a North Platte, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elucid

Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe